Table 3.

Summary of analyses of relative reduction of ovarian and tubal cancer deaths

	Number of women (n)	Deaths (n)	Maximum χ2 or mortality reduction (hazard ratio)	p value
Primary analysis*(ovarian and tubal cancer deaths)
MMS	50 625	296	0·41	0·58
USS	50 622	291	1·23	0·36
No screening	101 314	619	..	..
Subgroup outcome analysis*(invasive epithelial ovarian and tubal cancer)
MMS	50 625	295	0·41	0·60
USS	50 622	287	1·37	0·33
No screening	101 314	617	..	..
Secondary analysis†(all data 2001–20)
MMS	50 625	296	0·96 (0·83 to 1·10; 0·068)	0·52
USS	50 622	291	0·94 (0·82 to 1·08; 0·067)	0·37
No screening	101 314	619	..	..
Secondary analysis†(only data 2015–20)
MMS	45 999	136	1·05 (0·86 to 1·30; 0·112)	0·63
USS	46 079	128	0·99 (0·80 to 1·22; 0·107)	0·91
No screening	91 808	258	..	..

Data are maximum χ² for primary and subgroup analyses or mortality reduction (95% CI; SE) for secondary analyses. MMS=multimodal screening. USS=ultrasound screening.

^*Versatile test.

^†Cox model.